Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
ANG-1, Human recombinant protein
Angiopoietin-1
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | Q15389 |
|---|---|
| Calculated MW | 60-70 kDa |
| Gene ID | 284 |
|---|---|
| Gene Symbol | ANGPT1 |
| Other Names | Angiopoietin-1 |
| Gene Source | Human |
| Source | HeLa cells |
| Assay&Purity | SDS-PAGE; ≥95% |
| Assay2&Purity2 | HPLC; |
| Recombinant | Yes |
| Sequence | SNQRRSPENS GRRYNRIQHG QCAYTFILPE HDGNCRESTT DQYNTNALQR DAPHVEPDFS SQKLQHLEHV MENYTQWLQK LENYIVENMK SEMAQIQQNA VQNHTATMLE IGTSLLSQTA EQTRKLTDVE TQVLNQTSRL EIQLLENSLS TYKLEKQLLQ QTNEILKIHE KNSLLEHKIL EMEGKHKEEL DTLKEEKENL QGLVTRQTYI IQELEKQLNR ATTNNSVLQK QQLELMDTVH NLVNLCTKEG VLLKGGKREE EKPFRDCADV YQAGFNKSGI YTIYINNMPE PKKVFCNMDV NGGGWTVIQH REDGSLDFQR GWKEYKMGFG NPSGEYWLGN EFIFAITSQR QYMLRIELMD WEGNRAYSQY DRFHIGNEKQ NYRLYLKGHT GTAGKQSSLI LHGADFSTKD ADNDNCMCKC ALMLTGGWWF DACGPSNLNG MFYTAGQNHG KLNGIKWHYF KGPSYSLRST TMMIRPLDFH HHHHH |
| Target/Specificity | ANG-1 |
| Application Notes | Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C. |
| Format | Lyophilized powder |
| Storage | -20°C; Sterile filtered through a 0.2 micron filter. Lyophilized from 20 mM Sodium Phosphate, pH 7.5, 200 mM NaCl, 5% Trehalose. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Angiopoietin-1 (Ang-1) is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 (Ang-2), a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury (ALI) has recently been studied in a rat model of ALI. The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury (ARDI), a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 – 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.
References
Davis S.,et al.Cell 87:1161-1169(1996).
Nakatsukasa M.,et al.Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
Shan Z.X.,et al.Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
Nomura N.,et al.DNA Res. 1:27-35(1994).
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
